Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study

Anat Achiron; Mathilda Mandel; Sapir Dreyer-Alster; Gil Harari; Mark Dolev; Shay Menascu; David Magalashvili; Shlomo Flechter; Uri Givon; Diana Guber; Polina Sonis; Rina Zilkha-Falb; Michael Gurevich

doi:10.1016/j.jneuroim.2021.577746

Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study

Anat Achiron
, Mathilda Mandel
, Sapir Dreyer-Alster
, Gil Harari
, Mark Dolev
, Shay Menascu
, David Magalashvili
, Shlomo Flechter
, Uri Givon
, Diana Guber
, Polina Sonis
, Rina Zilkha-Falb
, Michael Gurevich

School of Public Health

Research output: Contribution to journal › Article › peer-review

Abstract

Appropriate immune response following COVID-19 vaccination is important in the context of disease-modifying treatments (DMTs). In a prospective cross-sectional study, we determined SARS-COV-2 IgG response up to 6 months following PfizerBNT162b2 vaccination in 414 multiple sclerosis (MS) patients and 89 healthy subjects. Protective response was demonstrated in untreated MS patients (N = 76, 100%), treated with Cladribine (N = 48, 100%), Dimethyl fumarate (N = 35, 100%), Natalizumab (N = 32, 100%), and Teriflunomide (N = 39, 100%), similarly to healthy subjects (N = 89, 97.8%). Response was decreased in Fingolimod (N = 42, 9.5%), Ocrelizumab (N = 114, 22.8%) and Alemtuzumab (N = 22, 86.4%) treated patients. IgG response can help tailor adequate vaccine guidelines for MS patients under various DMTs.

Original language	English
Article number	577746
Journal	Journal of Neuroimmunology
Volume	361
DOIs	https://doi.org/10.1016/j.jneuroim.2021.577746
State	Published - 15 Dec 2021

Bibliographical note

Publisher Copyright:
© 2021 Elsevier B.V.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

COVID-19
Disease modifying treatments
Humoral immunity
IgG antibody
Multiple sclerosis
Vaccination

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Neurology
Clinical Neurology

Access to Document

10.1016/j.jneuroim.2021.577746

Cite this

Achiron, A., Mandel, M., Dreyer-Alster, S., Harari, G., Dolev, M., Menascu, S., Magalashvili, D., Flechter, S., Givon, U., Guber, D., Sonis, P., Zilkha-Falb, R., & Gurevich, M. (2021). Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study. Journal of Neuroimmunology, 361, Article 577746. https://doi.org/10.1016/j.jneuroim.2021.577746

@article{e950c2cd7fb9452abe1baf77cc8b9fac,

title = "Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study",

abstract = "Appropriate immune response following COVID-19 vaccination is important in the context of disease-modifying treatments (DMTs). In a prospective cross-sectional study, we determined SARS-COV-2 IgG response up to 6 months following PfizerBNT162b2 vaccination in 414 multiple sclerosis (MS) patients and 89 healthy subjects. Protective response was demonstrated in untreated MS patients (N = 76, 100\%), treated with Cladribine (N = 48, 100\%), Dimethyl fumarate (N = 35, 100\%), Natalizumab (N = 32, 100\%), and Teriflunomide (N = 39, 100\%), similarly to healthy subjects (N = 89, 97.8\%). Response was decreased in Fingolimod (N = 42, 9.5\%), Ocrelizumab (N = 114, 22.8\%) and Alemtuzumab (N = 22, 86.4\%) treated patients. IgG response can help tailor adequate vaccine guidelines for MS patients under various DMTs.",

keywords = "COVID-19, Disease modifying treatments, Humoral immunity, IgG antibody, Multiple sclerosis, Vaccination",

author = "Anat Achiron and Mathilda Mandel and Sapir Dreyer-Alster and Gil Harari and Mark Dolev and Shay Menascu and David Magalashvili and Shlomo Flechter and Uri Givon and Diana Guber and Polina Sonis and Rina Zilkha-Falb and Michael Gurevich",

note = "Publisher Copyright: {\textcopyright} 2021 Elsevier B.V.",

year = "2021",

month = dec,

day = "15",

doi = "10.1016/j.jneuroim.2021.577746",

language = "English",

volume = "361",

journal = "Journal of Neuroimmunology",

issn = "0165-5728",

publisher = "Elsevier",

}

Achiron, A, Mandel, M, Dreyer-Alster, S, Harari, G, Dolev, M, Menascu, S, Magalashvili, D, Flechter, S, Givon, U, Guber, D, Sonis, P, Zilkha-Falb, R & Gurevich, M 2021, 'Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study', Journal of Neuroimmunology, vol. 361, 577746. https://doi.org/10.1016/j.jneuroim.2021.577746

TY - JOUR

T1 - Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination

T2 - Up to 6 months cross-sectional study

AU - Achiron, Anat

AU - Mandel, Mathilda

AU - Dreyer-Alster, Sapir

AU - Harari, Gil

AU - Dolev, Mark

AU - Menascu, Shay

AU - Magalashvili, David

AU - Flechter, Shlomo

AU - Givon, Uri

AU - Guber, Diana

AU - Sonis, Polina

AU - Zilkha-Falb, Rina

AU - Gurevich, Michael

PY - 2021/12/15

Y1 - 2021/12/15

N2 - Appropriate immune response following COVID-19 vaccination is important in the context of disease-modifying treatments (DMTs). In a prospective cross-sectional study, we determined SARS-COV-2 IgG response up to 6 months following PfizerBNT162b2 vaccination in 414 multiple sclerosis (MS) patients and 89 healthy subjects. Protective response was demonstrated in untreated MS patients (N = 76, 100%), treated with Cladribine (N = 48, 100%), Dimethyl fumarate (N = 35, 100%), Natalizumab (N = 32, 100%), and Teriflunomide (N = 39, 100%), similarly to healthy subjects (N = 89, 97.8%). Response was decreased in Fingolimod (N = 42, 9.5%), Ocrelizumab (N = 114, 22.8%) and Alemtuzumab (N = 22, 86.4%) treated patients. IgG response can help tailor adequate vaccine guidelines for MS patients under various DMTs.

AB - Appropriate immune response following COVID-19 vaccination is important in the context of disease-modifying treatments (DMTs). In a prospective cross-sectional study, we determined SARS-COV-2 IgG response up to 6 months following PfizerBNT162b2 vaccination in 414 multiple sclerosis (MS) patients and 89 healthy subjects. Protective response was demonstrated in untreated MS patients (N = 76, 100%), treated with Cladribine (N = 48, 100%), Dimethyl fumarate (N = 35, 100%), Natalizumab (N = 32, 100%), and Teriflunomide (N = 39, 100%), similarly to healthy subjects (N = 89, 97.8%). Response was decreased in Fingolimod (N = 42, 9.5%), Ocrelizumab (N = 114, 22.8%) and Alemtuzumab (N = 22, 86.4%) treated patients. IgG response can help tailor adequate vaccine guidelines for MS patients under various DMTs.

KW - COVID-19

KW - Disease modifying treatments

KW - Humoral immunity

KW - IgG antibody

KW - Multiple sclerosis

KW - Vaccination

UR - https://www.scopus.com/pages/publications/85116922368

U2 - 10.1016/j.jneuroim.2021.577746

DO - 10.1016/j.jneuroim.2021.577746

M3 - Article

C2 - 34655991

AN - SCOPUS:85116922368

SN - 0165-5728

VL - 361

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

M1 - 577746

ER -

Humoral immune response in multiple sclerosis patients following PfizerBNT162b2 COVID19 vaccination: Up to 6 months cross-sectional study

Abstract

Bibliographical note

UN SDGs

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this